Moreover, our study supported a promising therapeutic role of USP13 in prostate cancer: small molecular inhibitors targeting USP13 may improve the antitumor effects of DDR inhibitors and enhance innate immunity and immune infiltration, which might provide a new chance for immunotherapy to PCa patients. This evidence concerns the gene USP13 and posterior cortical atrophy.